A Comparative Assessment Study of Known Small-molecule GPVI Modulators.

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• The glycoprotein VI (GPVI) platelet receptor is a validated target for antiplatelet therapy in thrombosis.
• Existing small-molecule GPVI antagonists are often weakly potent and lack robust validation.
• Previous studies faced challenges comparing efficacy due to donor variability in assays.

Purpose of the Study:

• To conduct the first side-by-side assessment of reported small-molecule GPVI antagonists.
• To characterize the functional activities and binding of these modulators.
• To identify the most viable small-molecule GPVI modulators for further development.

Main Methods:

• Functional assays: Flow cytometry, light transmission aggregometry, and electrical impedance aggregometry to assess platelet activation and aggregation.
• Binding assays: Microscale thermophoresis (MST) and saturation transfer difference (STD) NMR to confirm GPVI binding.
• Computational methods: Molecular modeling to predict potential binding interactions.

Main Results:

• A comprehensive functional and binding characterization of multiple GPVI small-molecule modulators was performed.
• Losartan and a specific compound, designated as compound 5, were identified as the most promising GPVI modulators among those tested.
• Binding interactions were elucidated using biophysical techniques and molecular modeling.

Conclusions:

• Losartan and compound 5 represent the most viable small-molecule GPVI modulators currently available.
• This study provides a critical comparative analysis, addressing limitations of previous research.
• The findings support the continued investigation of these compounds for antiplatelet therapy.